Transactions with Major GABA Manufacturers in China and Expanded Order Intake
First written in FY2016-Q3. 6 of 13 entries say "Restated". Latest entry: FY2022.
Pharma Foods International moved to the "Worse" side of this theme in 2019, 2 years before the typical company in this theme (2021).
The whole theme swung hardest in 2020: 5 of 24 companies on the "Worse" side.
2 other companies' latest entry also says "Worsened".
- FY2022WorsenedAnnual report
「Overseas markets were affected, particularly by the lockdowns in China.」
The impact of lockdowns on full-year overseas sales of functional ingredients, including GABA, in China has been confirmed. - FY2022-Q3WorsenedAnnual report
「Overseas markets were affected, particularly by the lockdowns in China.」
The company reported the impact of lockdowns on sales from overseas sales of functional ingredients, including GABA, in China. - FY2020-Q3ReframedAnnual report
「In China in particular, demand for BonepepⓇ increased among food and dairy manufacturers. As part of its sales strategy, the company is working to build the BonepepⓇ brand in the country.」
The company’s China-related business has expanded its focus beyond conventional transactions with major GABA manufacturers to demand for Bonepep among food and dairy manufacturers and branding initiatives. - FY2020-Q1WorsenedAnnual report
「Meanwhile, overseas sales declined in China due to the impact of trade friction between China and the United States, leaving total sales in the functional ingredients business at approximately the same level as in the previous year.」
Overseas sales of functional ingredients in China declined due to the impact of China-US trade friction, resulting in deterioration in the performance of China-related transactions. - FY2019-Q2RestatedAnnual report
「The international business also performed well in both North America and China.」
The company continues to expand GABA in China, but no new large orders or number of business partners was explicitly reported. - FY2019-Q1RestatedAnnual report
「GABA continued to make steady progress in both North America and China.」
The company continues to expand GABA in China. No new large orders or number of business partners in China was explicitly reported. - FY2018-Q3RestatedAnnual report
「In the international business, the company continues to focus on GABA in both North America and China, while Bonepep has also performed steadily in China, contributing to the expansion of the functional ingredients business.」
The company reconfirmed its continued focus on GABA in China and Bonepep’s solid performance there. No new large orders or expansion of business partners was explicitly reported. - FY2018-Q2RestatedAnnual report
「In the international business, the company continues to focus on GABA in both North America and China, while Bonepep has also performed steadily in China, contributing to the expansion of the functional ingredients business.」
The company continues to focus on GABA in China and reported that Bonepep also remained firm in the Chinese market this time. - FY2018-Q1RestatedAnnual report
「In China, our GABA has been adopted by several global manufacturers.」
The company reconfirmed GABA adoption by several global manufacturers in China. No new information on sales growth or expanded orders was provided. - FY2017-Q3RestatedAnnual report
「In China, our GABA has been adopted by several global manufacturers since the previous fiscal year.」
The company reconfirmed GABA adoption by several global manufacturers in China. This filing contains no description of sluggish sales reported in the previous quarter, but it does not explicitly indicate a recovery in sales or expanded orders. - FY2017-Q2WorsenedAnnual report
「In China, our GABA has been adopted by several global manufacturers since the previous fiscal year, but sales remained sluggish during the cumulative second-quarter consolidated period.」
While adoption by several global manufacturers in China has continued, sales during the cumulative period of the current quarter were described as sluggish, indicating deterioration from the earlier trend of expanding orders and sales growth. - FY2017-Q1AdvancedAnnual report
「In the overseas expansion of GABA, it has been adopted by several major global manufacturers in China, driving sales growth.」
The company reported adoption by major manufacturers in China and sales growth, representing progress from the start of transactions and large orders reported in the previous fiscal year. - FY2016-Q3First statedAnnual report
「Overseas, we began trading GABA with several major global manufacturers in China in the previous fiscal year. After continuing to pursue an active sales strategy in the current fiscal year, we continued to secure large orders and achieved substantial sales growth.」
The company began trading with major manufacturers in China and reported continued large orders and sales growth.